Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity

被引:97
作者
de Haan, L
Verweij, WR
Holtrop, M
Brands, R
van Scharrenburg, GJM
Palache, AM
Agsteribbe, E
Wilschut, J
机构
[1] Univ Groningen, Dept Med Microbiol, Mol Virol Sect, NL-9713 AV Groningen, Netherlands
[2] Solvay Pharmaceut, NL-1381 CP Weesp, Netherlands
关键词
D O I
10.1016/S0264-410X(00)00556-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Local mucosal IgA antibodies play a central role in protection of the respiratory tract against influenza virus infection. Therefore, new-generation influenza vaccines should aim at stimulating not only systemic, but also local antibody responses. Previously, we demonstrated that the recombinant B subunit of the Escherichia coli heat-labile toxin (LTB) is a potent adjuvant towards nasally administered influenza subunit antigen. Here, we investigated the protection conferred by LTB-supplemented influenza subunit antigen given intranasally (i.n.) or intramuscularly (i.m.) to mice. Both i.n. and i.m. immunization with subunit antigen and LTB completely protected the animals against viral infection. Protection upon i.n. immunization was associated with the induction of antigen-specific serum IgG and mucosal IgA, whereas protection upon i.m. immunization correlated with strong serum and mucosal IgG, but not IgA responses. We conclude that LTB-supplemented influenza subunit antigen, given either i.n. or i.m, induces protective antibody-mediated mucosal immunity and thus represents a promising novel flu vaccine candidate. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2898 / 2907
页数:10
相关论文
共 46 条
[1]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[2]   SELECTIVE SOLUBILIZATION OF HEMAGGLUTININ AND NEURAMINIDASE FROM INFLUENZA-VIRUSES [J].
BACHMAYER, H .
INTERVIROLOGY, 1975, 5 (05) :260-272
[3]   Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization [J].
Barackman, JD ;
Ott, G ;
O'Hagan, DT .
INFECTION AND IMMUNITY, 1999, 67 (08) :4276-4279
[4]  
Blanchard TG, 1998, IMMUNOLOGY, V94, P22
[5]  
BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13
[6]   Immune functions and immunopathology of the mucosa of the upper respiratory pathways [J].
Brandtzaeg, P ;
Jahnsen, FL ;
Farstad, IN .
ACTA OTO-LARYNGOLOGICA, 1996, 116 (02) :149-159
[7]   The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT) [J].
Cheng, E ;
Cárdenas-Freytag, L ;
Clements, JD .
VACCINE, 1999, 18 (1-2) :38-49
[8]   Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus [J].
Claas, ECJ ;
Osterhaus, ADME ;
van Beek, R ;
De Jong, JC ;
Rimmelzwaan, GF ;
Senne, DA ;
Krauss, S ;
Shortridge, KF ;
Webster, RG .
LANCET, 1998, 351 (9101) :472-477
[9]   MUCOSAL VACCINES FOR THE PREVENTION OF INFLUENZA [J].
CLANCY, RL .
DRUGS, 1995, 50 (04) :587-594
[10]  
CLEMENTS ML, 1986, J CLIN MICROBIOL, V24, P269